Moreover, MitoTEMPO inhibits ROS production, increases intrahepatic CD4+ T lymphocyte counts, and delays the development of hepatocellular carcinoma (HCC) induced by MASLD (125). Here, CD4 is linked to hepatocellular carcinoma.